SG Americas Securities LLC Sells 13,575 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

SG Americas Securities LLC reduced its holdings in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 66.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 6,978 shares of the company's stock after selling 13,575 shares during the period. SG Americas Securities LLC's holdings in Mirum Pharmaceuticals were worth $289,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. grew its position in Mirum Pharmaceuticals by 22.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company's stock valued at $67,000 after acquiring an additional 318 shares during the last quarter. Avanza Fonder AB bought a new position in Mirum Pharmaceuticals during the fourth quarter valued at approximately $189,000. Y Intercept Hong Kong Ltd bought a new position in Mirum Pharmaceuticals during the third quarter valued at approximately $215,000. Creative Planning bought a new position in Mirum Pharmaceuticals during the third quarter valued at approximately $249,000. Finally, China Universal Asset Management Co. Ltd. grew its position in Mirum Pharmaceuticals by 65.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,176 shares of the company's stock valued at $358,000 after acquiring an additional 3,639 shares during the last quarter.

Mirum Pharmaceuticals Trading Down 0.3 %

MIRM stock traded down $0.17 on Friday, reaching $51.06. The company's stock had a trading volume of 616,405 shares, compared to its average volume of 532,217. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34. The firm has a market cap of $2.45 billion, a PE ratio of -25.28 and a beta of 0.96. The business has a fifty day simple moving average of $44.80 and a two-hundred day simple moving average of $42.33. Mirum Pharmaceuticals, Inc. has a 12-month low of $23.14 and a 12-month high of $53.49.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.15. The business had revenue of $90.38 million during the quarter, compared to analyst estimates of $81.99 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The company's revenue for the quarter was up 89.4% on a year-over-year basis. During the same quarter last year, the firm posted ($0.57) earnings per share. As a group, research analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.44 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. Leerink Partners raised their target price on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an "outperform" rating in a report on Thursday, October 17th. HC Wainwright restated a "buy" rating and issued a $66.00 target price on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Robert W. Baird raised their target price on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an "outperform" rating in a report on Wednesday, November 13th. Finally, Citigroup raised their target price on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a "buy" rating in a report on Wednesday, November 13th. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $57.10.

Insider Transactions at Mirum Pharmaceuticals

In other news, COO Peter Radovich sold 2,627 shares of Mirum Pharmaceuticals stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $48.22, for a total value of $126,673.94. Following the completion of the transaction, the chief operating officer now owns 26,961 shares of the company's stock, valued at $1,300,059.42. The trade was a 8.88 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Christopher Peetz sold 7,489 shares of Mirum Pharmaceuticals stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total value of $320,678.98. Following the completion of the transaction, the chief executive officer now directly owns 119,359 shares of the company's stock, valued at approximately $5,110,952.38. This represents a 5.90 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 43,415 shares of company stock valued at $2,015,670 in the last quarter. 22.87% of the stock is owned by insiders.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.